腹腔免疫化疗对晚期消化道肿瘤合并癌性腹水患者近期生存质量的影响

Effects of Immunocheotheroapy via Abdominal Cavity on Life Quality of Patients with Advanced Digestive System Neoplasms with Ascites

目的:探讨腹腔免疫化疗对晚期消化道肿瘤合并癌性腹水患者的近期生存质量的影响。方法:28例消化道肿瘤合并癌性腹水患者采用顺铂(DDP)加高聚金葡素(HASL)或白介素2(IL-2)进行腹腔灌注治疗,予B超测定患者治疗前、后腹水变化及Karnofsky评分增加、腹胀改善、乏力、胃肠道反应及白细胞减少等情况。结果:腹腔免疫化疗治疗消化道肿瘤合并癌性腹水有效率82.1%,与对照组(52.9%)比较,有显著性差异。治疗组生活质量提高,包括Karnofsky评分的增加、腹胀的减轻及出现胃肠道反应等,分别为75%、82.1%、35.7%,与对照组的41.2%、55.9%、64.7%相比较,有显著性差异(P<0.05)。结论:腹腔免疫化疗对晚期消化道肿瘤合并癌性腹水的治疗是一种安全、简便、有效的新方法,可以明显提高患者近期生存质量。

Objective.To evaluate the effects of abdominal cavity immunochemofherapy on life quality of patients with advanced digestive system neoplasms with ascites. Methods：Twenty-eight eases of advanced digetive system neoplasms with ascites were treated with intra-peritoneal injection of DDP and IL-2 or HASL. The amount of ascites were determined by B ultrasongraph,Karnofsky giving a mark, appetite and biodynamia,gastrointesinal effect and bloated abdomen before and after the treatment. Results. The effective rate, gastrointestinal effect, Karnofsky giving a mark increasing and bloated abdomen were 82.1%, 75 %, 82. 1% and 35.7 %, respectively, in treatment group, while 52. 9%,41.2%, 55. 9% and 64.7% respectively, in control group（P〈0. 01）. Conclusion：Abdominal cavity immunochemotherapy can improve the life quality of the patients with advancted digestive system neoplasms with ascites.